obviously LEO thinks there is value in ATryn to spend a sizable sum on a P2 DIC trial
why ask? you see companies like LEVP and ENCY bought out for large sums... in the hundreds of millions dollars... considering the product purchased.
to me / and i suspect others on this board GTC has multiple times the potential of an ENCY or a LEVP... certainly many more products in development (for better or worse)
so are the $$$ spent in research $$$ thrown down a rat's hole when it comes to valuing GTC?
Look @ the amounts spent to date to develop the drugs now in GTC's pipeline by GTC and its partners... and these are in most cases not new molecules... i.e. #msg-22016210 (they are low risk programs)...
when does this translate to value? My point is GTC's pipeline is not being valued for what it is worth... not even close.
The creation of a thousand forests is in one acorn.
Market Data 
Markets 
AI
